Oncimmune Holdings PLC (LON:ONC) said its Brazilian distributor has received the regulatory all-clear for its lung cancer detection blood test, paving the way for sales in the country.
Marketing authorisation for the EarlyCDT Lung product is effective immediately, providing partner Valentech International commercial access to one of the world’s largest healthcare markets.
Brazil has a high unmet need for a diagnostic that could help cut the mortality rate for the disease. Figures for 2018 showed 34,000 people were diagnosed with lung cancer and there were 32,000 deaths that year.
"Survival rates from lung cancer can be increased significantly with earlier detection of the disease. We are delighted that EarlyCDT Lung can now be made available in this large market, where the need is so great,” said Dr Adam Hill, Oncimmune chief executive in s statement.